Silexion Therapeutics Corp (SLXN) - Q1 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2026. Silexion Therapeutics Corp is a clinical-stage biotechnology company developing RNA interference (RNAi) therapies for KRAS-driven cancers, with its lead candidate being SIL204. The company operates primarily through its Israeli subsidiary, Silexion Therapeutics Ltd. As of the reporting date, the company has not generated any revenue from product sales and remains in a development stage.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(2,733,000) | $(1,735,000) |
| Operating Expenses | $2,749,000 | $1,650,000 |
| Cash and Cash Equivalents (End of Period) | $2,413,000 | $6,152,000 |
| Net Cash Used in Operating Activities | $(3,646,000) | $(2,453,000) |
| Shareholders' Equity | $291,000 | $2,586,000 |
| Related Party Promissory Note Outstanding | $1,553,000 | $1,568,000 |
Material Changes vs. Prior Period
- Increased Operating Loss: Net loss increased by approximately 59% to $2.73 million, driven primarily by a 133% increase in Research and Development (R&D) expenses to $1.37 million. This increase was due to costs associated with toxicology studies and GMP manufacturing to support a planned human clinical trial in Q2 2026.
- Higher G&A Expenses: General and Administrative expenses rose 27% to $1.38 million, largely due to increased professional services (legal, investor relations) and share-based compensation.
- Cash Burn: Cash and cash equivalents decreased by approximately $3.6 million during the quarter, reflecting the negative operating cash flow of $3.65 million.
- Equity Dilution: The company issued 64,080 ordinary shares under its At-The-Market (ATM) facility during the quarter, raising approximately $76,000 net of costs.
Outlook, Risks, and Subsequent Events
- Going Concern Warning: Management has concluded there is substantial doubt about the company's ability to continue as a going concern. Current cash reserves are estimated to fund operations for only "several months" from the filing date. Additional financing is required to fund clinical trials and maintain operations.
- Nasdaq Compliance: As of March 31, 2026, shareholders' equity ($291,000) was below the Nasdaq Capital Market minimum requirement of $2.5 million. However, subsequent financing activities in May 2026 restored equity above this threshold.
- Subsequent Financing (May 2026):
- Completed an induced warrant exercise transaction raising approximately $1.0 million gross.
- Sold shares under the ATM facility in April and May 2026, raising approximately $1.08 million net.
- Converted portions of the Related Party Promissory Note into ordinary shares.
- Reverse Share Split: Shareholders approved a 1-for-10 reverse share split in May 2026 to maintain compliance with Nasdaq minimum bid price requirements. This is expected to become effective in late May or early June 2026.
- Geopolitical Risk: The company notes ongoing hostilities in the Middle East (Israel/Iran/Hezbollah). While core R&D activities are conducted outside Israel, the conflict poses risks to travel, fundraising, and general operations.
Key Facts for Investor Verification
- Liquidity Runway: Verify the sufficiency of cash raised in May 2026 to fund operations through the initiation of the planned Q2 2026 clinical trial for SIL204.
- Nasdaq Status: Confirm the successful implementation of the 1-for-10 reverse share split and continued compliance with Nasdaq listing standards (minimum bid price and shareholders' equity).
- Related Party Note Dispute: Monitor the status of the dispute with the Moringa Sponsor regarding the conversion of the Related Party Promissory Note into shares, as the Sponsor has demanded repayment in full.
- Clinical Trial Timeline: Track the actual initiation date of the human clinical trial for SIL204, which was expected in Q2 2026 but is contingent on regulatory clearance and funding.
- Share Count: Note that all share data in this report is pre-reverse split; verify post-split share counts and per-share metrics once the 1-for-10 split is effective.